Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series

Pediatr Allergy Immunol. 2015 Sep;26(6):585-8. doi: 10.1111/pai.12407. Epub 2015 Jun 14.

Authors

Elena Netchiporouk¹, Christopher H Nguyen¹, Thusanth Thuraisingham¹, Fatemeh Jafarian¹, Marcus Maurer², Moshe Ben-Shoshan³

Affiliations

¹ Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada.
² Department of Dermatology and Allergy, Charité Universitätsmedizin, Berlin, Germany.
³ Department of Pediatrics, Division of Allergy and Clinical Immunology, McGill University Health Centre, Montreal, QC, Canada. moshebenshoshan@gmail.com.

PMID: 26012951
DOI: 10.1111/pai.12407

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Child
Child, Preschool
Chronic Disease
Female
Humans
Immunologic Factors / administration & dosage
Immunologic Factors / therapeutic use*
Injections, Subcutaneous
Male
Omalizumab / administration & dosage
Omalizumab / therapeutic use*
Remission Induction
Severity of Illness Index
Time Factors
Treatment Outcome
Urticaria / diagnosis
Urticaria / drug therapy*
Urticaria / etiology

Substances

Immunologic Factors
Omalizumab